Avascular Necrosis Market: Increase in the prevalence of Avascular Necrosis and Technological advancements in the treatment of avascular necrosis to boost market growth

Global Avascular Necrosis Market size was valued at USD 652.73 Mn in 2023 and is expected to reach USD 1001.08 Mn by 2030, at a CAGR of 6.3 %.

Avascular Necrosis Market Overview

Avascular necrosis is a disease that results from the temporary (short-term) or permanent (lifelong) loss of the blood supply of the bone. It is also known as Osteonecrosis and AVN. It is a degenerative bone condition characterized by the death of the cellular components of the bone secondary to an interruption of the subchondral blood diseases. The factors that develop the risk of Avascular necrosis include trauma, use of the steroid, drinking too much alcohol, use of bisphosphate and taking certain medical treatments such as radiation therapy for cancer and organ transplant. The report includes historical data, present and future trends, competitive environment of the Avascular necrosis industry. The market revenue is determined by the primary and secondary data collection methods. The bottom-up approach was used to estimate the Avascular necrosis market size.

Avascular Necrosis MarketTo know about the Research Methodology :- Request Free Sample Report

Avascular Necrosis Market Dynamics

The rise in the aging population, the growing number of knee replacements and hip surgeries, the increase in the use of diagnostic centers for trauma-related cases and new products launched by the key players are the growth contributing factors for the Avascular Necrosis Market. The increase in the prevalence of Avascular Necrosis due to increasing consumption of alcohol, and tobacco consumption, the growing number of drug approvals from the regulatory bodies and a rise in the risk of several chronic diseases including arthritis, diabetes and HIV are also factors that fuel the market growth. Avascular Necrosis Market Drivers The growing number of road accidents, traumatic injuries and increasing incidence of Legg-Calvé-Perthes disease (LCPD) in children to boosts the market growth Avascular Necrosis is caused by an injury including a forceful impact in a car crash or occurs as a complication of the dislocation or hip fracture. In road accidents, due to crashes of the vehicles, the humans face major problems such as broken bones and dislocated hips and it also creates the problem of the cuts off the blood flow. Traumatic injuries are formed when the blood supply to the femoral head is due to the dislocation and fracture of the femoral head. Trauma injuries such as fractures to the neck of the talus are very common and they happen due to vehicle collisions, falls, sports injuries, natural disasters and other physical industries that occur at home while doing work and on the street. Additionally, in children, Avascular Necrosis also occurs mainly from cancer therapy. The Legg-Calvé-Perthes disease (LCPD) is an Avascular Necrosis of the proximal femoral head and it commonly occurs in children aged 4-10 years. As a result, the growing number of road accidents, traumatic injuries and increasing incidence in children fuel the Avascular Necrosis Market demand. Technological advancements in the treatment of avascular necrosis to fuel the market growth The bone marrow and aspirate and the concentration is a new innovative and helpful procedure that introduces the avascular necrosis of the hip in the early stages. While doing surgery on bone marrow, the surgeon detaches the sample of the dead hipbone and inserts the stem cells taken from the bone marrow in its place. Thus bone marrow and aspirate and concentration surgery is the widely used technology for the treatment of avascular necrosis. The permanent solution of avascular necrosis (AVN) is Bone cell therapy conducted by using the patient’s own cells as a therapeutic tool to heal AVN. Bone cell therapy ceases the disease progression and restores mobility. Tissue engineering is another regenerative medicine strategy that helps to regenerate the vasculature in the femoral head which is the vital cause of the disease and it also helps the regeneration of the necrotic bone tissues. As a result, all the advanced techniques for the treatment of avascular necrosis are expected to influence the Avascular Necrosis Market growth. Avascular Necrosis Market Restraints The high cost of Avascular Necrosis treatments, several risk factors associated with the drug treatment and the lack of knowledge about the symptoms of Avascular Necrosis among the population. The strict regulatory requirements and the availability of alternative treatments are also restraining factors for market growth.

Avascular Necrosis Market Regional Insights

North America dominated the Avascular Necrosis Market with the largest revenue share in 2023 and is expected to continue its dominance over the forecast period. The regional market is driven by the presence of the major key players, growing adoption of advanced treatment options, advanced healthcare infrastructure, and high concentration of the relevance of Avascular Necrosis in individuals. The increasing geriatric population, increasing prevalence of Avascular Necrosis, favorable reimbursement policies, growing awareness regarding Avascular Necrosis among the people, increasing healthcare spending and the increasing number of inorganic growth strategies by key players are the influencing factors for the Avascular Necrosis Market. Asia Pacific is expected to have a significant growth rate for the Avascular Necrosis industry over the forecast period. The growing number of patients suffering from, Avascular Necrosis, the presence of the large population, increasing government initiatives for promoting awareness about Avascular Necrosis, improvement in the healthcare infrastructure, rising healthcare expenditure, and increasing prevalence of bone disorders in developing economies such as India and China.

Avascular Necrosis Market Segment Analysis

Based on Disease Type On the basis of the disease type, the market is categorized into Traumatic Avascular Necrosis and Non-Traumatic Avascular Necrosis. In 2023, Traumatic Avascular Necrosis dominated the market with the largest revenue share and is expected to dominate the market over the forecast period. The segment is driven by the increasing trauma injuries such as dislocation or fracture, increase in the use of the steroid and bisphosphates and drinking too much alcohol. When traumatic avascular necrosis occurs, the blood supply to the head of the femur has been simply disrupted and leading to avascular necrosis. Avascular necrosis or osteonecrosis results in 15 % to 50 % of the fractures of the neck of the femur and 10% to 25 % of the hip dislocations. Approximately, 20 percent of the people who dislocate their hips cause avascular necrosis. Avascular Necrosis Market Based on Treatment Type On the basis of the Treatment Type, the market is divided mainly into Drug and therapy. The Drug type is categorized into Nonsteroidal anti-inflammatory drugs, Osteoporosis drugs, Cholesterol-lowering drugs, Blood Thinner and Others. Nonsteroidal anti-inflammatory drugs are expected to have the highest growth rate in the market. Over-the-counter medications such as ibuprofen or naproxen sodium Nonsteroidal anti-inflammatory drugs help to relieve pain associated with avascular necrosis. The Nonsteroidal anti-inflammatory drugs taper off steroids and offer a total hip replacement. It is used to manage the early symptoms of the disease. All the mentioned factors help to grow the Nonsteroidal anti-inflammatory drugs segment. Therapy type is categorized into Electrical Stimulation, Rest, Exercise and Gene therapy and Surgery. During the forecast period, Electrical Stimulation is expected to have significant growth due to the Electrical currents has been encouraging the body to grow new bone to replace the damaged bone and used during surgery and applied directly to the damaged area. Also, Gene therapy and surgery are expected to have the fastest growing segments over the forecast period. Avascular Necrosis Market Based on Diagnosis On the basis of the Diagnosis, the market is categorized into Imaging, Biopsy, Total, CT scan and PET and X-ray. MRI is expected to grow significantly in the avascular necrosis market during the forecast period. MRI is the more sensitive test for the diagnosis of avascular necrosis and it is much more sensitive than plain film radiography used for the detection of AVN. The MRI creates 3D images of the bone and provides a detailed view of the bone. It diagnoses a bone condition more accurately and definitely than another diagnosis process. Thus, MRI and CT scan is the most dominant and useful process.

Avascular Necrosis Market Competitive Landscape

The global market include several Avascular Necrosis Market key players at country, regional and global levels. These key players are adopting several strategies including investments, partnerships, mergers and acquisitions and joint ventures. Some of the Avascular Necrosis key players are the Wright Medical Group Inc., Bone Therapeutics SA, Medtronic Logo, Teva Pharmaceuticals Industries Ltd., DR. Reddys Laboratories Ltd., Solara Active Pharma Sciences Limited, Bayer AG, ALkem labs and others. These key players have adopted strategies including pricing investments, expansion of the product portfolio, mergers and acquisition collaboration, agreements and geographical expansion for the enhancement of the Avascular Necrosis industry. The companies conducted research and development activities regarding bone diseases. Bone Therapeutics SA develops innovative allogeneic product, ALLOB, which currently targets a bone indication and offers the possibility of extending the product portfolio to other bone defects.

Avascular Necrosis Market Scope: Inquire before buying

Avascular Necrosis Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: USD 652.73 Mn
Forecast Period 2024 to 2030 CAGR: 6.3 % Market Size in 2030: USD 1001.08 Mn
Segments Covered: by Disease Type 1. Traumatic Avascular Necrosis 2. Non-Traumatic Avascular Necrosis
by Treatment Type 1 Drug Type 1.1Nonsteroidal anti-inflammatory drugs 1.2 Ibuprofen 1.3 Naproxen Sodium 1.4 Osteoporosis drugs 1.5 Cholesterol-lowering drugs 1.6 Blood Thinners 1.7 Others 2 Therapy 2.1 Electrical Stimulation 2.2Rest 2.3 Exercises 2.4 Gene therapy and Surgery
by Product 1. Tablets 2.Capsules 3.Suspension 4.Syrups 5. Injectable
by Diagnosis 1.Imaging 2.Biopsy 3.CT scan 4. PET and X-ray
by Route of Administration 1. Oral 2. Parenteral
by End User 1. Hospital Pharmacy 2. Online Pharmacy 3.Retail Pharmacy
by Distribution Channel 1. Offline 2. Online

Avascular Necrosis Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and the Rest of APAC) South America (Brazil, Argentina Rest of South America) Middle East & Africa (South Africa, GCC, Egypt, Nigeria and the Rest of ME&A)

Avascular Necrosis Key Players

1. Bone Therapeutics SA 2. Wright Medical Group Inc., 3. Medtronic Logo 4. Teva Pharmaceuticals Industries Ltd. 5. DR. Reddys Laboratories Ltd. 6. Solara Active Pharma Sciences Limited 7. Bayer AG 8. ALkem labs 9. Novartis AG 10.GSK 11.Pfizer,Inc. 12.Integra LifeSciences 13.Eli Lilly and Company 14.Medtronic Plc 15.Bristol Myers Squibb-Myers Squibb 16.Merck KGaA, Zimmer Biomet Holdings 17.Sanofi SA, Pfizer Inc., 18.Smith & Nephew Plc. 19.Integra LifeSciences Corporation 20.Stryker Corporation 21.Boehringer Ingelheim 22.Zimmer Biom 23.Johnson & Johnson et 24.Baxter Frequently Asked Questions: 1] What is the growth rate of the Global Avascular Necrosis Market? Ans. The Global Avascular Necrosis Market is growing at a significant rate of 6.3 % during the forecast period. 2] Which region is expected to dominate the Global Avascular Necrosis Market? Ans. North America is expected to dominate the Avascular Necrosis Market during the forecast period. 3] What is the expected Global Avascular Necrosis Market size by 2030? Ans. The Avascular Necrosis Market size is expected to reach USD 1001.08 Mn by 2030. 4] Which are the top players in the Global Avascular Necrosis Market? Ans. The major top players in the Global Avascular Necrosis Market are Wright Medical Group Inc., Bone Therapeutics SA, Medtronic Logo, Teva Pharmaceuticals Industries Ltd., DR. Reddys Laboratories Ltd., Solara Active Pharma Sciences Limited, Bayer AG, ALkem labs and others. 5] What are the factors driving the Global Avascular Necrosis Market growth? Ans. The growing number of road accidents, traumatic injuries and increasing incidence of Legg-Calvé-Perthes disease (LCPD) in children and technological advancements in the treatment of avascular necrosis are expected to drive market growth during the forecast period.
1. Avascular Necrosis Market: Research Methodology 2. Avascular Necrosis Market: Executive Summary 3. Avascular Necrosis Market: Competitive Landscape 3.1. MMR Competition Matrix 3.2. Competitive Landscape 3.3. Key Players Benchmarking 3.4. Market Structure 3.4.1. Market Leaders 3.4.2. Market Followers 3.4.3. Emerging Players 3.5. Consolidation of the Market 4. Avascular Necrosis Market: Dynamics 4.1. Market Trends by region 4.1.1. North America 4.1.2. Europe 4.1.3. Asia Pacific 4.1.4. Middle East and Africa 4.1.5. South America 4.2. Market Drivers by Region 4.2.1. North America 4.2.2. Europe 4.2.3. Asia Pacific 4.2.4. Middle East and Africa 4.2.5. South America 4.3. Market Restraints 4.4. Market Opportunities 4.5. Market Challenges 4.6. PORTER’s Five Forces Analysis 4.7. PESTLE Analysis 4.8. Value Chain Analysis 4.9. Regulatory Landscape by Region 4.9.1. North America 4.9.2. Europe 4.9.3. Asia Pacific 4.9.4. Middle East and Africa 4.9.5. South America 5. Avascular Necrosis Market: Segmentation (by Value USD Units) 5.1. Avascular Necrosis Market, by Disease Type (2023-2030) 5.1.1. Traumatic Avascular Necrosis 5.1.2. Non-Traumatic Avascular Necrosis 5.2. Avascular Necrosis Market, by Treatment Type (2023-2030) 5.2.1. Drug 5.2.2. Therapy 5.3. Avascular Necrosis Market, by Product (2023-2030) 5.3.1. Tablets 5.3.2. Capsules 5.3.3. Suspension 5.3.4. Syrups 5.3.5. Injectable 5.4. Avascular Necrosis Market, by Diagnosis (2023-2030) 5.4.1. Imaging 5.4.2. Biopsy 5.4.3. CT scan 5.4.4. PET and X-ray 5.5. Avascular Necrosis Market, by Route of Administration (2023-2030) 5.5.1. Oral 5.5.2. Parenteral 5.6. Avascular Necrosis Market, by End User (2023-2030) 5.6.1. Hospital Pharmacy 5.6.2. Online Pharmacy 5.6.3. Retail Pharmacy 5.7. Avascular Necrosis Market, by Distribution Channel (2023-2030) 5.7.1. Offline 5.7.2. Online 5.8. Avascular Necrosis Market, by Region (2023-2030) 5.8.1. North America 5.8.2. Europe 5.8.3. Asia Pacific 5.8.4. Middle East and Africa 5.8.5. South America 6. North America Avascular Necrosis Market (by Value USD Units) 6.1. North America Avascular Necrosis Market, by Disease Type (2023-2030) 6.1.1. Traumatic Avascular Necrosis 6.1.2. Non-Traumatic Avascular Necrosis 6.2. North America Avascular Necrosis Market, by Treatment Type (2023-2030) 6.2.1. Drug 6.2.2. Therapy 6.3. North America Avascular Necrosis Market, by Product (2023-2030) 6.3.1. Tablets 6.3.2. Capsules 6.3.3. Suspension 6.3.4. Syrups 6.3.5. Injectable 6.4. North America Avascular Necrosis Market, by Diagnosis (2023-2030) 6.4.1. Imaging 6.4.2. Biopsy 6.4.3. CT scan 6.4.4. PET and X-ray 6.5. North America Avascular Necrosis Market, by Route of Administration (2023-2030) 6.5.1. Oral 6.5.2. Parenteral 6.6. North America Avascular Necrosis Market, by End User (2023-2030) 6.6.1. Hospital Pharmacy 6.6.2. Online Pharmacy 6.6.3. Retail Pharmacy 6.7. North America Avascular Necrosis Market, by Distribution Channel (2023-2030) 6.7.1. Offline 6.7.2. Online 6.8. North America Avascular Necrosis Market, by Country (2023-2030) 6.8.1. United States 6.8.2. Canada 6.8.3. Mexico 7. Europe Avascular Necrosis Market (by Value USD Units) 7.1. Europe Avascular Necrosis Market, by DiseaeseType (2023-2030) 7.2. Europe Avascular Necrosis Market, by Treatment Type (2023-2030) 7.3. Europe Avascular Necrosis Market, by Product (2023-2030) 7.4. Europe Avascular Necrosis Market, by Diagnosis (2023-2030) 7.5. Europe Avascular Necrosis Market, by Route of Administration(2023-2030) 7.6. Europe Avascular Necrosis Market, by End User (2023-2030) 7.7. Europe Avascular Necrosis Market, by Distribution Channel (2023-2030) 7.8. Europe Avascular Necrosis Market, by Country (2023-2030) 7.8.1. UK 7.8.2. France 7.8.3. Germany 7.8.4. Italy 7.8.5. Spain 7.8.6. Sweden 7.8.7. Austria 7.8.8. Rest of Europe 8. Asia Pacific Avascular Necrosis Market (by Value USD Units) 8.1. Asia Pacific Avascular Necrosis Market, by DiseaeseType (2023-2030) 8.2. Asia Pacific Avascular Necrosis Market, by Treatment Type (2023-2030) 8.3. Asia Pacific Avascular Necrosis Market, by Product (2023-2030) 8.4. Asia Pacific Avascular Necrosis Market, by Diagnosis (2023-2030) 8.5. Asia Pacific Avascular Necrosis Market, by Route of Administration(2023-2030) 8.6. Asia Pacific Avascular Necrosis Market, by End User (2023-2030) 8.7. Asia Pacific Avascular Necrosis Market, by Distribution Channel (2023-2030) 8.8. Asia Pacific Avascular Necrosis Market, by Country (2023-2030) 8.8.1. China 8.8.2. S Korea 8.8.3. Japan 8.8.4. India 8.8.5. Australia 8.8.6. Indonesia 8.8.7. Malaysia 8.8.8. Vietnam 8.8.9. Taiwan 8.8.10. Bangladesh 8.8.11. Pakistan 8.8.12. Rest of Asia Pacific 9. Middle East and Africa Avascular Necrosis Market (by Value USD Units) 9.1. Middle East and Africa Avascular Necrosis Market, by DiseaeseType (2023-2030) 9.2. Middle East and Africa Avascular Necrosis Market, by Treatment Type (2023-2030) 9.3. Middle East and Africa Avascular Necrosis Market, by Product (2023-2030) 9.4. Middle East and Africa Avascular Necrosis Market, by Diagnosis (2023-2030) 9.5. Middle East and Africa Avascular Necrosis Market, by Route of Administration(2023-2030) 9.6. Middle East and Africa Avascular Necrosis Market, by End User (2023-2030) 9.7. Middle East and Africa Avascular Necrosis Market, by Distribution Channel (2023-2030) 9.8. Middle East and Africa Avascular Necrosis Market, by Country (2023-2030) 9.8.1. South Africa 9.8.2. GCC 9.8.3. Egypt 9.8.4. Nigeria 9.8.5. Rest of ME&A 10. South America Avascular Necrosis Market (by Value USD and Volume Units) 10.1. South America Avascular Necrosis Market, by DiseaeseType (2023-2030) 10.2. South America Avascular Necrosis Market, by Treatment Type (2023-2030) 10.3. South America Avascular Necrosis Market, by Product (2023-2030) 10.4. South America Avascular Necrosis Market, by Diagnosis (2023-2030) 10.5. South America Avascular Necrosis Market, by Route of Administration(2023-2030) 10.6. South America Avascular Necrosis Market, by End User (2023-2030) 10.7. South America Avascular Necrosis Market, by Distribution Channel (2023-2030) 10.8. South America Avascular Necrosis Market, by Country (2023-2030) 10.8.1. Brazil 10.8.2. Argentina 10.8.3. Rest of South America 11. Company Profile: Key players 11.1. Bone Therapeutics SA 11.1.1. Company Overview 11.1.2. Financial Overview 11.1.3. Business Portfolio 11.1.4. SWOT Analysis 11.1.5. Business Strategy 11.1.6. Recent Developments 11.2. Bone Therapeutics SA 11.3. Wright Medical Group Inc., 11.4. Medtronic Logo 11.5. Teva Pharmaceuticals Industries Ltd. 11.6. DR. Reddys Laboratories Ltd. 11.7. Solara Active Pharma Sciences Limited 11.8. Bayer AG 11.9. ALkem labs 11.10. Novartis AG 11.11. GSK 11.12. Pfizer,Inc. 11.13. Integra LifeSciences 11.14. Eli Lilly and Company 11.15. Medtronic Plc 11.16. Bristol Myers Squibb-Myers Squibb 11.17. Merck KGaA, Zimmer Biomet Holdings 11.18. Sanofi SA, Pfizer Inc., 11.19. Smith & Nephew Plc. 11.20. Integra LifeSciences Corporation 11.21. Stryker Corporation 11.22. Boehringer Ingelheim 11.23. Zimmer Biom 11.24. Johnson & Johnson et 11.25. Baxter 12. Key Findings 13. Industry Recommendation
  • INQUIRE BEFORE BUYING
MMRLogo
America's Fastest Growing Market Research Firm